May 6 (Reuters) – Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine supply and licensing deals helped offset pressure from sagging demand.
First-quarter revenue came in at $139.5 million, topping analysts’ estimate of $78.3 million, according to LSEG-compiled data.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath)
Comments